Drug Type Small molecule drug |
Synonyms GLPG 0974 |
Target |
Mechanism FFAR2 antagonists(Free fatty acid receptor 2 antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC25H25ClN2O4S |
InChIKeyMPMKMQHJHDHPBE-RUZDIDTESA-N |
CAS Registry1391076-61-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Colitis, Ulcerative | Phase 2 | BE | 01 Apr 2013 | |
Colitis, Ulcerative | Phase 2 | CZ | 01 Apr 2013 | |
Colitis, Ulcerative | Phase 2 | LV | 01 Apr 2013 | |
Colitis, Ulcerative | Phase 2 | SK | 01 Apr 2013 |
Phase 1 | - | - | ojahcjqmup(tktkewuskq) = daily dose of 400 mg dqczkygjap (lyraurpjiw ) | Positive | 01 Jul 2016 | ||
Phase 2 | Colitis, Ulcerative Geboes scores | Fecal calprotectin (FC) | 45 | GLPG0974 200 mg b.i.d. | sxxepkwcwh(abtmeoltfu) = no serious infections and a low frequency of common infections favoring GLPG0974 (n=1) over placebo (n=3) orqtmqdimd (lrwcocubke ) | Positive | 19 Jan 2015 | |
Placebo | |||||||
Phase 1 | - | dbthjihbyg(gvdfejchxr) = GLPG0974 substantially inhibited acetate-stimulated neutrophil activation in whole blood oxsuczpaot (fattmbvxdq ) View more | Positive | 01 Feb 2014 |